• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《达格列净对接受托伐普坦治疗的常染色体显性多囊肾病患者影响的开放标签、随机、对照、交叉试验》勘误 [第10卷,第4期,2025年4月,第1063 - 1075页]

Erratum to "Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan" [ Volume 10, Issue 4, April 2025, Pages 1063-1075].

作者信息

Uchiyama Kiyotaka, Kamano Daisuke, Nagasaka Tomoki, Hama Eriko Yoshida, Shirai Ryoichi, Sumura Rena, Kusahana Ei, Yanai Akane, Nakayama Takashin, Kimura Takahide, Takahashi Rina, Kasai Takahiro, Tajima Takaya, Hosoya Koji, Azegami Tatsuhiko, Yamaguchi Shintaro, Yoshino Jun, Ito Jun, Hayashi Matsuhiko, Kanda Takeshi, Ishibashi Yoshitaka, Washida Naoki, Itoh Hiroshi, Hayashi Kaori

机构信息

Department of Nephrology, International University of Health and Welfare Narita Hospital, Chiba, Japan.

Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan.

出版信息

Kidney Int Rep. 2025 May 16;10(7):2505-2506. doi: 10.1016/j.ekir.2025.05.025. eCollection 2025 Jul.

DOI:10.1016/j.ekir.2025.05.025
PMID:40677357
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12266208/
Abstract

[This corrects the article DOI: 10.1016/j.ekir.2025.01.023.].

摘要

[本文更正了文章的数字对象标识符:10.1016/j.ekir.2025.01.023。]

相似文献

1
Erratum to "Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan" [ Volume 10, Issue 4, April 2025, Pages 1063-1075].《达格列净对接受托伐普坦治疗的常染色体显性多囊肾病患者影响的开放标签、随机、对照、交叉试验》勘误 [第10卷,第4期,2025年4月,第1063 - 1075页]
Kidney Int Rep. 2025 May 16;10(7):2505-2506. doi: 10.1016/j.ekir.2025.05.025. eCollection 2025 Jul.
2
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.达格列净对接受托伐普坦治疗的常染色体显性多囊肾病患者疗效的开放标签、随机、对照、交叉试验
Kidney Int Rep. 2025 Jan 18;10(4):1063-1075. doi: 10.1016/j.ekir.2025.01.023. eCollection 2025 Apr.
3
Erratum to "Survey on Plasmapheresis Practices in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Insights From Two Clinical Case Studies" [ Volume 10, Issue 4, April 2025, Pages 1292-1295].《抗中性粒细胞胞浆自身抗体相关血管炎血浆置换实践调查:来自两个临床病例研究的见解》勘误[第10卷,第4期,2025年4月,第1292 - 1295页]
Kidney Int Rep. 2025 May 17;10(7):2507-2508. doi: 10.1016/j.ekir.2025.05.028. eCollection 2025 Jul.
4
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [ Volume 10, Issue 4, April 2025, Pages 1283-1287].《使用国际IgA肾病预测工具丰富临床试验队列》的勘误[第10卷,第4期,2025年4月,第1283 - 1287页]
Kidney Int Rep. 2025 May 16;10(7):2506. doi: 10.1016/j.ekir.2025.05.026. eCollection 2025 Jul.
5
Erratum to "Advancing Understanding of Mitochondrial Function in Diabetic Kidney Disease" [ Volume 10, Issue 2, February 2025, Pages 285-286].《对“深化对糖尿病肾病中线粒体功能的理解”的勘误》[第10卷,第2期,2025年2月,第285 - 286页]
Kidney Int Rep. 2025 Apr 11;10(6):2080. doi: 10.1016/j.ekir.2025.04.011. eCollection 2025 Jun.
6
Erratum to "Extrarenal Clinical Features are Reported for Most Genes Implicated in Genetic Kidney Disease" [ Volume 10, Issue 4, April 2025, Pages 1196-1204].《遗传性肾脏病相关大多数基因的肾外临床特征报告》勘误[第10卷,第4期,2025年4月,第1196 - 1204页]
Kidney Int Rep. 2025 May 17;10(7):2508-2509. doi: 10.1016/j.ekir.2025.05.029. eCollection 2025 Jul.
7
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.用于预防常染色体显性遗传性多囊肾病进展的干预措施。
Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.
8
Erratum to "Patient and Provider Attitudes Toward Patient-Facing Kidney Organ Offer Reporting" [ Volume 10, Issue 4, April 2025, Pages 1122-1130].《“患者及医疗服务提供者对面向患者的肾脏器官供体报告的态度”勘误》[第10卷,第4期,2025年4月,第1122 - 1130页]
Kidney Int Rep. 2025 May 17;10(7):2505. doi: 10.1016/j.ekir.2025.05.024. eCollection 2025 Jul.
9
Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series.托伐普坦与达格列净联合治疗常染色体显性多囊肾病的肾脏保护作用:四例病例系列报道
CEN Case Rep. 2025 Jun;14(3):500-506. doi: 10.1007/s13730-025-00990-7. Epub 2025 Apr 11.
10
Erratum to "Discordant Results Between Creatinine- and Cystatin C-based Equations for Estimating GFR" [ Volume 10, Issue 4, April 2025, Pages 1248-1259].《基于肌酐和胱抑素C的估算肾小球滤过率方程结果不一致》勘误 [第10卷,第4期,2025年4月,第1248 - 1259页]
Kidney Int Rep. 2025 May 17;10(7):2507. doi: 10.1016/j.ekir.2025.05.027. eCollection 2025 Jul.